Back to Search Start Over

Construction of 3D and 2D contrast-enhanced CT radiomics for prediction of CGB3 expression level and clinical prognosis in bladder cancer.

Authors :
Zhang Y
Xu Z
Wu S
Zhu T
Hong X
Chi Z
Malla R
Jiang J
Huang Y
Xu Q
Wang Z
Zhang Y
Source :
Heliyon [Heliyon] 2023 Sep 20; Vol. 9 (9), pp. e20335. Date of Electronic Publication: 2023 Sep 20 (Print Publication: 2023).
Publication Year :
2023

Abstract

Objective: The purpose of this study was to construct a 3D and 2D contrast-enhanced computed tomography (CECT) radiomics model to predict CGB3 levels and assess its prognostic abilities in bladder cancer (Bca) patients.<br />Methods: Transcriptome data and CECT images of Bca patients were downloaded from The Cancer Imaging Archive (TCIA) and The Cancer Genome Atlas (TCGA) database. Clinical data of 43 cases from TCGA and TCIA were used for radiomics model evaluation. The Volume of interest (VOI) (3D) and region of interest (ROI) (2D) radiomics features were extracted. For the construction of predicting radiomics models, least absolute shrinkage and selection operator regression were used, and the filtered radiomics features were fitted using the logistic regression algorithm (LR). The model's effectiveness was measured using 10-fold cross-validation and the area under the receiver operating characteristic curve (AUC of ROC).<br />Result: CGB3 was a differential expressed prognosis-related gene and involved in the immune response process of plasma cells and T cell gamma delta. The high levels of CGB3 are a risk element for overall survival (OS). The AUCs of VOI and ROI radiomics models in the training set were 0.841 and 0.776, while in the validation set were 0.815 and 0.754, respectively. The Delong test revealed that the AUCs of the two models were not statistically different, and both models had good predictive performance.<br />Conclusion: The CGB3 expression level is an important prognosis factor for Bca patients. Both 3D and 2D CECT radiomics are effective in predicting CGB3 expression levels.<br />Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.<br /> (© 2023 The Authors.)

Details

Language :
English
ISSN :
2405-8440
Volume :
9
Issue :
9
Database :
MEDLINE
Journal :
Heliyon
Publication Type :
Academic Journal
Accession number :
37809854
Full Text :
https://doi.org/10.1016/j.heliyon.2023.e20335